NTLA

Intellia Therapeutics Inc.

Price

$13.28

return (12m)

29.06%

p/e

-3.93

p/bv

2.16

DIVIDEND YIELD

0.00%

NTLA price

Intellia Therapeutics

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment NTLA

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

16.29%

3 months

7.36%

1 year

29.06%

2 years

-43.34%

5 years

-91.11%

10 years

0.00%

Asset Comparator

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Fundamentals NTLA

Valuation

P/E

-3.93

Sector -4.38

Industry -4.38

P/BV

2.16

Sector 2.02

Industry 2.02

P/Revenue (PSR)

26.39

Sector -4.40

Industry -4.40

EV/EBITDA

-10.24

Sector -263.09

Industry -263.09

EV/EBIT

-10.05

Sector -702.90

Industry -702.90

P/EBITDA

-3.85

Sector -4.39

Industry -4.39

P/EBIT

-3.71

Sector -4.73

Industry -4.73

P/Total Assets

1.83

Sector 1.49

Industry 1.49

P/Net Current Assets

3.94

Sector -11.70

Industry -11.70

P/Working Capital

3.50

Sector -3.19

Industry -3.19

EPS

-3.01

Sector -2.14

Industry -2.14

BVPS

5.47

Sector 1.85

Industry 1.85

Efficiency

Gross Margin

100.00%

Sector 36.74%

Industry 36.74%

EBITDA Margin

-1,444.91%

Sector -16,244.81%

Industry -16,244.81%

EBIT Margin

-1,472.06%

Sector -4,202,541.34%

Industry -4,202,541.34%

Operating Margin

-100.00%

Sector -38.22%

Industry -38.22%

Net Profit Margins

-100.00%

Sector -39.69%

Industry -39.69%

Asset Turnover

0.01

Sector 0.03

Industry 0.03

Profitability

ROE

-54.96%

Sector -65.14%

Industry -65.14%

ROA

-46.66%

Sector -65.53%

Industry -65.53%

ROIC

-126.49%

Sector -2,103.35%

Industry -2,103.35%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

Sector -

Industry -

Debt

Current Ratio

6.65

Sector 2.90

Industry 2.90

Net Debt / EBITDA

3.96

Sector -6.07

Industry -6.07

Net Debt / EBIT

3.88

Sector -8.26

Industry -8.26

Net Debt / Equity

-0.60

Sector -1.07

Industry -1.07

Gross Debt / Equity

0.00

Sector -0.05

Industry -0.05

Equity/Assets

0.85

Sector 0.41

Industry 0.41

Liabilities/Assets

0.15

Sector 0.39

Industry 0.39

Growth

5Y Revenue CAGR

12.48%

Sector -

Industry -

5Y Earnings CAGR

8.35%

Sector -

Industry -

Fundamentals NTLA

DRAG THE FRAME TO SEE MORE DATA

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
NTLA Intellia Therapeutics Inc.	$13.28	23.77%	0.00%	-3.93	2.16	-54.96%	-100.00%
JNJ Johnson & Johnson	$273.41	58.46%	2.02%	29.66	7.34	24.76%	21.48%
PFE Pfizer Inc.	$28.24	21.45%	6.54%	34.62	1.75	5.07%	6.80%
ABBV AbbVie Inc.	$265.97	33.11%	2.73%	70.02	-74.53	-106.44%	9.81%
NVO Novo Nordisk A/S	$46.48	-9.14%	4.09%	11.13	5.91	53.11%	35.32%
MRK Merck & Co. Inc.	$152.20	87.95%	2.45%	106.68	8.06	7.56%	4.77%
AZN AstraZeneca PLC	$164.95	4.92%	2.07%	22.98	4.77	20.74%	17.02%
BMY Bristol-Myers Squibb Company	$67.61	46.95%	3.93%	14.06	5.85	41.59%	18.87%
ZTS Zoetis Inc.	$76.68	-48.52%	2.77%	11.89	9.88	83.10%	27.49%
REGN Regeneron Pharmaceuticals Inc.	$840.84	43.05%	0.45%	19.09	2.61	13.65%	27.86%
AMGN Amgen Inc.	$442.36	55.11%	2.39%	25.30	18.93	74.80%	22.95%
HALO Halozyme Therapeutics Inc.	$107.62	56.06%	0.00%	27.82	80.17	288.14%	24.86%
MCK McKesson Corporation	$853.71	27.85%	0.38%	22.42	-79.15	-352.96%	1.12%
VRTX Vertex Pharmaceuticals Incorporated	$552.06	41.60%	0.00%	29.26	6.36	21.76%	35.00%
CAH Cardinal Health Inc.	$234.85	58.85%	0.88%	31.61	-19.89	-62.92%	0.67%
HRMY Harmony Biosciences Holdings Inc.	$39.93	9.67%	0.00%	12.18	2.21	18.14%	18.89%
BIIB Biogen Inc.	$221.56	63.02%	0.00%	37.04	1.64	4.43%	8.32%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

NTLA Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT Intellia Therapeutics

Intellia Therapeutics Inc.

Average Investor10 user rating

4.0 (5 people)

United States

12 years

Founded: 2014

2016

Time since IPO - 10 years

312

Employees

Intellia Therapeutics Inc. (United States) is listed on the Nasdaq and has a market capitalization of $1.57 billion, with shareholders equity totaling $727.71 million.

The company employs approximately 312 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Intellia Therapeutics Inc. reported $59.51 million in revenue, generating net income of $-399.97 million.

Key financial metrics include a P/E ratio of -3.93, a price-to-book (P/B) ratio of 2.16, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker NTLA.

Market cap

$1.57 billion

Net worth

$727.71 million

$727,710,000.00

Assets

$857.16 million

$857,160,000.00

Total Shares Outstanding

133.00 million

133,000,000

Average Daily Trading Volume

$5.16 million

$5,157,546.00

Sector

Health Care

Industry

Biotechnology

NTLA

NTLA revenue and profits

Financial Results NTLA

DRAG THE FRAME TO SEE MORE DATA

NTLA cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$853.71 22,07% (12M)

P/E

22.42

0.38%

ROE

-352.96%

P/BV

-79.15

CAH - Cardinal Health

$234.85 55,51% (12M)

P/E

31.61

0.88%

ROE

-62.92%

P/BV

-19.89

JNJ - Johnson & Johnson

$273.41 57,54% (12M)

P/E

29.66

2.02%

ROE

24.76%

P/BV

7.34

ABBV - AbbVie

$265.97 31,23% (12M)

P/E

70.02

2.73%

ROE

-106.44%

P/BV

-74.53

MRK - Merck & Co.

$152.20 86,97% (12M)

P/E

106.68

2.45%

ROE

7.56%

P/BV

8.06

AZN - AstraZeneca

$164.95 5,00% (12M)

P/E

22.98

2.07%

ROE

20.74%

P/BV

4.77

PFE - Pfizer

$28.24 21,16% (12M)

P/E

34.62

6.54%

ROE

5.07%

P/BV

1.75

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$853.71 22,07% (12 M)

P/L

22.42

0.38%

ROE

-352.96%

P/VP

-79.15

CAH - Cardinal Health

$234.85 55,51% (12 M)

P/L

31.61

0.88%

ROE

-62.92%

P/VP

-19.89

JNJ - Johnson & Johnson

$273.41 57,54% (12 M)

P/L

29.66

2.02%

ROE

24.76%

P/VP

7.34

ABBV - AbbVie

$265.97 31,23% (12 M)

P/L

70.02

2.73%

ROE

-106.44%

P/VP

-74.53

MRK - Merck & Co.

$152.20 86,97% (12 M)

P/L

106.68

2.45%

ROE

7.56%

P/VP

8.06

AZN - AstraZeneca

$164.95 5,00% (12 M)

P/L

22.98

2.07%

ROE

20.74%

P/VP

4.77

PFE - Pfizer

$28.24 21,16% (12 M)

P/L

34.62

6.54%

ROE

5.07%

P/VP

1.75

Frequently Asked Questions

What is the price of Intellia Therapeutics (NTLA) today?

A cotação de Intellia Therapeutics (NTLA) hoje está em US$ 13.28, com uma variação de 29.06% em relação ao último ano. A cotação de Intellia Therapeutics (NTLA) iniciou o ano negociando na casa dos US$ 8.99 e hoje está em US$ 13.28. Acompanhe o gráfico de cotação em tempo real, a cotação histórica de Intellia Therapeutics (NTLA) e dados de ações do Ibovespa e mercados internacionais.

Quando Intellia Therapeutics (NTLA) paga dividendos?

Intellia Therapeutics (NTLA) não distribuiu dividendos no último ano.

Is Intellia Therapeutics (NTLA) a good investment?

Atualmente, Intellia Therapeutics (NTLA) está cotada a US$ 13.28, com um P/L de -3.93, representando um desvio de -408% em relação ao seu P/L médio histórico. No último ano, a ação apresentou uma variação de 29.06 em sua cotação e distribuiu US$ 0.00 em dividendos, resultando em um Dividend Yield de 0.00%. O retorno total do acionista foi de 29.06%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Intellia Therapeutics (NTLA) stock?

Investir em ações de Intellia Therapeutics (NTLA) pode ser feito de duas formas: comprando a stock uma empresa estrangeira e é atrelado ao dólar.

How much would 100 shares of Intellia Therapeutics (NTLA) yield today?

A rentabilidade de Intellia Therapeutics (NTLA) foi de 16.29% no último mês, 29.06% no último ano e -91.11% nos últimos 5 anos (já considerando valorização e dividendos).

Nos últimos 12 meses, a empresa pagou um total de US$ 0.00 em dividendos, um Dividend Yield de 0.00%.

Se você quisesse comprar 100 ações de Intellia Therapeutics (NTLA) hoje, o investimento total seria de US$ 1,328.00, com base na cotação atual de US$ 13.28.

Based on historical performance, the investment would have grown to approximately:

Em 1 ano: US$ 1,713.92
Em 5 anos: US$ 118.06
Em 10 anos: US$ 1,328.00

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

NTLA

Intellia Therapeutics Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment NTLA

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

COMPARING NTLA WITH OTHER STOCK

current DY: 0.00%

5-year average DY: 0.00%

ABOUT Intellia Therapeutics

Intellia Therapeutics Inc.

United States

12 years

2016

312

PROFIT X PRICE NTLA

Financial Results NTLA

NTLA cash flow

Asset, Revenue and Profit Growth - NTLA

NTLA balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

Frequently Asked Questions